SuperworthAurinia Pharmaceuticals profit margin AUPH
Gross, operating and net profit as a share of revenue over the last twelve months, from 2022.
- Net margin, 12 months
- n/m
- not a meaningful number
- Operating margin, 12 months
- 48.4%
- Peer median
- 11.1%
Aurinia Pharmaceuticals' net margin works out at 101% over the last twelve months, but it is not a meaningful number: a margin outside minus 100% to 100% is moved by items that are not sales.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | n/a | 37.1% | 88.5% |
| FY2024 | 2.4% | −2.0% | 88.0% |
| FY2023 | −44.5% | −52.2% | 91.9% |
| FY2022 | −80.7% | −83.2% | 95.8% |
| FY2021 | n/a | n/a | 97.6% |
| FY2020 | n/a | n/a | 100.0% |
| FY2019 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | n/a | n/a | 48.4% | |
| Q1 FY26 | 100.0% | +83.9 pts | 41.7% | |
| Q4 FY25 | n/a | n/a | 37.1% | |
| Q3 FY25 | 29.3% | +39.5 pts | 26.3% | |
| Q2 FY25 | 23.3% | +47.6 pts | 20.0% | |
| Q1 FY25 | 16.1% | +48.8 pts | 12.3% | |
| Q4 FY24 | 2.4% | +46.9 pts | −2.0% | |
| Q3 FY24 | −10.2% | +38.4 pts | −14.8% | |
| Q2 FY24 | −24.3% | +21.1 pts | −29.3% | |
| Q1 FY24 | −32.7% | +33.2 pts | −39.4% | |
| Q4 FY23 | −44.5% | +36.3 pts | −52.2% | |
| Q3 FY23 | −48.6% | +40.9 pts | −56.7% |
Against its peers
Companies in Drug Manufacturers - General nearest Aurinia Pharmaceuticals' size, closest first, today.
| Company | Profit margin |
|---|---|
| AUPHAurinia Pharmaceuticals | n/m |
| PBHPrestige Consumer Healthcare | 15.6% |
| HRMYHarmony Biosciences | 18.9% |
| NRIXNurix Therapeutics | 42.0% |
| ANIPANI Pharmaceuticals | 11.1% |
| PAHCPhibro Animal Health | 6.6% |
| ANABAnaptysbio | n/m |
| PCRXPacira BioSciences | 2.0% |
| OGNOrganon | 3.4% |
| LQDALiquidia | 30.7% |
| ARQTArcutis Biotherapeutics | 6.1% |
| Peer median | 11.1% |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Aurinia Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.